Sign in to fuzzto save your conversations, follow your research and come back anytime.
Sun Pharmaceutical
SUNPHARMA
NSE
BSE
NSEBSESectorHealthcare
1,916.00
Loading chart…
About the company
Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun Pharma has a strong presence in India and the US, which account for about 70% of its revenue. It operates 43 manufacturing facilities worldwide and invests 7-8% of revenue in R&D annually. The company has expanded through acquisitions and licensing deals to strengthen its specialty and generic portfolios. Key specialty products include Ilumya, Winlevi, Cequa and others in dermatology, ophthalmology and oncology. Sun Pharma supplies medicines to over 100 countries and has manufacturing facilities across six continents.
In the news
Brokerages Eye L&T, Sun Pharma, SBI Life for Trading Opportunities
Sun Pharma, Cipla offer better upside: Systematix
Sun Pharma Shares Rise 0.36% After Bernstein, HSBC Maintain Bullish Ratings
Sun Pharma wins Lipitor antitrust lawsuit appeal in US court
Sun Pharma Faces Major Legal Setback in Semaglutide Launch
Bajaj Broking picks Sun Pharma, BEL for 6-month rally
India's Outbound M&A Evolution: From Scale to Capability
Sun Pharma shares fall 2% despite strong Q1 results beating expectations
Sun Pharma Q1FY27: ₹15,183 cr revenue, target price ₹2,310
Brokerages update ratings: Tata Steel, Maruti Suzuki, GAIL
Sun Pharma Eye Drop Recall: A Crisis of Quality and Confidence
Sun Pharma Recalls 10 Eye Drop Brands Over Contamination
Sun Pharma Launches Semaglutide in Brazil Through Hypera Partnership
Sun Pharma Q1 results: 27% PAT growth to ₹2,895 cr, 80%+ gross margin sustainable
Sun Pharma inches closer to record $12B Organon buyout after shareholder approval
Market Experts' Stock Picks: Buy ICICI Bank, Hold Reliance Industries
Trump's 200% tariff plan could benefit Indian pharma long-term: Bernstein
Trump's 200% Generic Drug Tariff Plan: Indian Pharma Stocks Crash Up to 4%
Trump finalizes 200% tariffs on generic medicines from 2028
Sun Pharma hits 52-week high after SA approves generic Semaglutide